MIM
AVBP icon

MetLife Investment Management’s ArriVent BioPharma AVBP Stock Holding History

MetLife Investment Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$400K Buy
17,324
+667
+4% +$15.1K ﹤0.01% 1859
2025
Q4 		$335K Sell
16,657
-453
-3% -$9.43K ﹤0.01% 1994
2025
Q3 		$316K Hold
17,110
– – ﹤0.01% 2052
2025
Q2 		$372K Hold
17,110
– – ﹤0.01% 1817
2025
Q1 		$316K Sell
17,110
-350
-2% -$8.56K ﹤0.01% 1941
2024
Q4 		$465K Buy
17,460
+1,110
+7% +$31.9K ﹤0.01% 1843
2024
Q3 		$384K Buy
16,350
+10,269
+169% +$233K ﹤0.01% 1924
2024
Q2 		$113K Buy
6,081
+567
+10% +$10.1K ﹤0.01% 2550
2024
Q1 		$98.5K Buy
+5,514
New +$111K ﹤0.01% 2547

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MetLife Investment Management's AVBP Position: Q1 2026 in Review

MetLife Investment Management increased its ArriVent BioPharma (AVBP) stake by 4% in Q1 2026, buying an estimated $15.1K and bringing the position to 17,324 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #1859.

MetLife Investment Management first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $465K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • MetLife Investment Management held 17,324 shares of ArriVent BioPharma worth $400K as of Q1 2026.
  • MetLife Investment Management bought 667 ArriVent BioPharma shares in Q1 2026, an estimated $15.1K.
  • ArriVent BioPharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1859 holding.
  • MetLife Investment Management first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • MetLife Investment Management's ArriVent BioPharma position peaked at $465K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.